York Trials Unit, Department of Health Sciences, University of York, ARRC Building, York, YO10 5DD, UK.
Chesterfield Hospital, Chesterfield Road, Calow, S44 5BL, UK.
Osteoporos Int. 2019 Aug;30(8):1543-1559. doi: 10.1007/s00198-019-04949-0. Epub 2019 May 10.
Vitamin K may affect bone mineral density and fracture incidence. Since publication of a previous systematic review the integrity of some of the previous evidence has been questioned and further trials have been published. Therefore an update to the systematic review was required.
This systematic review was designed to assess the effectiveness of oral vitamin K supplementation for increasing bone mineral density and reducing fractures in adults.
MEDLINE, EMBASE, CENTRAL, CINAHL, clinicaltrials.gov, and WHO-ICTRP were searched for eligible trials. Randomised controlled trials assessing oral vitamin K supplementation that assessed bone mineral density or fractures in adult populations were included. A total of 36 studies were identified. Two independent reviewers extracted data using a piloted extraction form.
For post-menopausal or osteoporotic patients, meta-analysis showed that the odds of any clinical fracture were lower for vitamin K compared to controls (OR, 0.72, 95%CI 0.55 to 0.95). Restricting the analysis to low risk of bias trials reduced the OR to 0.76 (95%CI, 0.58 to 1.01). There was no difference in vertebral fractures between the groups (OR 0.96, 95%CI 0.83 to 1.11). In the bone mineral density meta-analysis, percentage change from baseline at the lumbar spine was higher at 1 year (MD 0.93, 95%, CI - 0.02 to 1.89) and 2 years (MD 1.63%, 95%CI 0.10 to 3.16) for vitamin K compared to controls; however, removing trials at high risk of bias tended to result in smaller differences that were not statistically significant. At 6 months, it was higher in the hip (MD 0.42%, 95%CI 0.01 to 0.83) and femur (MD 0.29%, 95%CI 0.17 to 0.42). There was no significant difference at other anatomical sites.
For post-menopausal or osteoporotic patients, there is no evidence that vitamin K affects bone mineral density or vertebral fractures; it may reduce clinical fractures; however, the evidence is insufficient to confirm this. There are too few trials to draw conclusions for other patient groups.
维生素 K 可能会影响骨密度和骨折发生率。自之前的系统评价发表以来,一些先前证据的完整性受到了质疑,并且已经发表了更多的试验。因此,需要对该系统评价进行更新。
本系统评价旨在评估口服维生素 K 补充剂对增加成年人骨密度和减少骨折的有效性。
检索了 MEDLINE、EMBASE、CENTRAL、CINAHL、clinicaltrials.gov 和 WHO-ICTRP 以获取合格的试验。纳入了评估口服维生素 K 补充剂对成年人群骨密度或骨折的随机对照试验。共确定了 36 项研究。两名独立的审查员使用预先制定的提取表格提取数据。
对于绝经后或骨质疏松症患者,与对照组相比,维生素 K 降低了任何临床骨折的几率(OR,0.72,95%CI 0.55 至 0.95)。将分析仅限于低偏倚风险的试验,将 OR 降低至 0.76(95%CI,0.58 至 1.01)。两组之间椎骨骨折无差异(OR 0.96,95%CI 0.83 至 1.11)。在骨密度荟萃分析中,与对照组相比,维生素 K 在第 1 年(MD 0.93,95%CI-0.02 至 1.89)和第 2 年(MD 1.63%,95%CI 0.10 至 3.16)时腰椎的基线百分比变化更高;然而,剔除高偏倚风险的试验往往会导致差异较小,且无统计学意义。在 6 个月时,髋关节(MD 0.42%,95%CI 0.01 至 0.83)和股骨(MD 0.29%,95%CI 0.17 至 0.42)的骨密度更高。在其他解剖部位无显著差异。
对于绝经后或骨质疏松症患者,没有证据表明维生素 K 会影响骨密度或椎骨骨折;它可能会减少临床骨折;但是,证据不足以证实这一点。对于其他患者群体,试验太少,无法得出结论。